TY - JOUR
T1 - Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection
AU - Johnston, Christine
AU - Magaret, Amalia
AU - Son, Hyunju
AU - Stern, Michael
AU - Rathbun, Molly
AU - Renner, Daniel
AU - Szpara, Moriah
AU - Gunby, Sarah
AU - Ott, Mariliis
AU - Jing, Lichen
AU - Campbell, Victoria L.
AU - Huang, Meei Li
AU - Selke, Stacy
AU - Jerome, Keith R.
AU - Koelle, David M.
AU - Wald, Anna
N1 - Funding Information:
reported receiving grants from National Institutes of Health/National Institute of Allergy and Infectious Diseases during the conduct of the study and personal fees from AbbVie, grants from Gilead, royalties from UpToDate, and personal fees from GlaxoSmithKline outside the submitted work. Dr Gunby reported being an IDSA Education and Research Foundation Scholarship recipient during the conduct of the study. Dr Koelle reported receiving grants from Sanofi (specifically a contract to perform immunogenicity assays for HSV-2 vaccine clinical trial) outside the submitted work and having a patent for HSV vaccine candidates with royalties paid from Immune Design Corporation; institutionally (university) owned patents were licensed by University of Washington to Immune Design Corporation and royalty payments were received. Dr Wald reported receiving grants from NIH during the conduct of the study and grants from GlaxoSmithKline and Sanofi and personal fees from Aicuris, X-Vax, Crozet, Auritec, and DxNow outside the submitted work. No other disclosures were reported.
Funding Information:
(Drs Johnston, Magaret, Huang, Jerome, Koelle, and Wald), NIH Contract 75N93019C00063 (Dr Koelle), National Institutes of Health (NIH) grants R01 AI132392 (Dr Szpara) and R21 AI130676 (Drs Szpara and Johnston). Dr Rathbun was supported in part by NIH T32 GM 102057-5 and a Pennsylvania State University Kern Graduate School Academic Computing Fellowship.
Publisher Copyright:
© 2022 American Medical Association. All rights reserved.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Importance: Herpes simplex virus type 1 (HSV-1) is the leading cause of first-episode genital herpes in many countries. Objective: To inform counseling messages regarding genital HSV-1 transmission, oral and genital viral shedding patterns among persons with first-episode genital HSV-1 infection were assessed. The trajectory of the development of HSV-specific antibody and T-cell responses was also characterized. Design, Setting, and Participants: Prospective cohort followed up for up to 2 years, with 82 participants followed up between 2013 and 2018. Participants were recruited from sexual health and primary care clinics in Seattle, Washington. Persons with laboratory-documented first-episode genital HSV-1 infection, without HIV infection or current pregnancy, were referred for enrollment. Exposures: First-episode genital HSV-1 infection. Main Outcomes and Measures: Genital and oral HSV-1 shedding and lesion rates at 2 months, 11 months, and up to 2 years after initial genital HSV-1 infection. Participants self-collected oral and genital swabs for HSV polymerase chain reaction testing for 30 days at 2 and 11 months and up to 2 years after diagnosis of genital HSV-1. Blood samples were collected at serial time points to assess immune responses to HSV-1. Primary HSV-1 infection was defined as absent HSV antibody at baseline or evolving antibody profile using the University of Washington HSV Western Blot. HSV-specific T-cell responses were detected using interferon γ enzyme-linked immunospot. Results: Among the 82 participants, the median (range) age was 26 (16-64) years, 54 (65.9%) were women, and 42 (51.2%) had primary HSV-1 infection. At 2 months, HSV-1 was detected from the genital tract in 53 participants (64.6%) and in the mouth in 24 participants (29.3%). Genital HSV-1 shedding was detected on 275 of 2264 days (12.1%) at 2 months and declined significantly to 122 of 1719 days (7.1%) at 11 months (model-predicted rate, 6.2% [95% CI, 4.3%-8.9%] at 2 months vs 3.2% [95% CI, 1.8%-5.7%] at 11 months; relative risk, 0.52 [95% CI, 0.29-0.93]). Genital lesions were rare, reported on 65 of 2497 days (2.6%) at 2 months and 72 of 1872 days (3.8%) at 11 months. Oral HSV-1 shedding was detected on 88 of 2247 days (3.9%) at 2 months. Persons with primary HSV-1 infection had a higher risk of genital shedding compared with those with nonprimary infection (model-predicted rate, 7.9% [95% CI, 5.4%-11.7%] vs 2.9% [95% CI, 1.7%-5.0%]; relative risk, 2.75 [95% CI, 1.40-5.44]). Polyfunctional HSV-specific CD4+ and CD8+ T-cell responses were maintained during the follow-up period. Conclusions and Relevance: Genital HSV-1 shedding was frequent after first-episode genital HSV-1, particularly among those with primary infection, and declined rapidly during the first year after infection..
AB - Importance: Herpes simplex virus type 1 (HSV-1) is the leading cause of first-episode genital herpes in many countries. Objective: To inform counseling messages regarding genital HSV-1 transmission, oral and genital viral shedding patterns among persons with first-episode genital HSV-1 infection were assessed. The trajectory of the development of HSV-specific antibody and T-cell responses was also characterized. Design, Setting, and Participants: Prospective cohort followed up for up to 2 years, with 82 participants followed up between 2013 and 2018. Participants were recruited from sexual health and primary care clinics in Seattle, Washington. Persons with laboratory-documented first-episode genital HSV-1 infection, without HIV infection or current pregnancy, were referred for enrollment. Exposures: First-episode genital HSV-1 infection. Main Outcomes and Measures: Genital and oral HSV-1 shedding and lesion rates at 2 months, 11 months, and up to 2 years after initial genital HSV-1 infection. Participants self-collected oral and genital swabs for HSV polymerase chain reaction testing for 30 days at 2 and 11 months and up to 2 years after diagnosis of genital HSV-1. Blood samples were collected at serial time points to assess immune responses to HSV-1. Primary HSV-1 infection was defined as absent HSV antibody at baseline or evolving antibody profile using the University of Washington HSV Western Blot. HSV-specific T-cell responses were detected using interferon γ enzyme-linked immunospot. Results: Among the 82 participants, the median (range) age was 26 (16-64) years, 54 (65.9%) were women, and 42 (51.2%) had primary HSV-1 infection. At 2 months, HSV-1 was detected from the genital tract in 53 participants (64.6%) and in the mouth in 24 participants (29.3%). Genital HSV-1 shedding was detected on 275 of 2264 days (12.1%) at 2 months and declined significantly to 122 of 1719 days (7.1%) at 11 months (model-predicted rate, 6.2% [95% CI, 4.3%-8.9%] at 2 months vs 3.2% [95% CI, 1.8%-5.7%] at 11 months; relative risk, 0.52 [95% CI, 0.29-0.93]). Genital lesions were rare, reported on 65 of 2497 days (2.6%) at 2 months and 72 of 1872 days (3.8%) at 11 months. Oral HSV-1 shedding was detected on 88 of 2247 days (3.9%) at 2 months. Persons with primary HSV-1 infection had a higher risk of genital shedding compared with those with nonprimary infection (model-predicted rate, 7.9% [95% CI, 5.4%-11.7%] vs 2.9% [95% CI, 1.7%-5.0%]; relative risk, 2.75 [95% CI, 1.40-5.44]). Polyfunctional HSV-specific CD4+ and CD8+ T-cell responses were maintained during the follow-up period. Conclusions and Relevance: Genital HSV-1 shedding was frequent after first-episode genital HSV-1, particularly among those with primary infection, and declined rapidly during the first year after infection..
UR - http://www.scopus.com/inward/record.url?scp=85141888287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141888287&partnerID=8YFLogxK
U2 - 10.1001/jama.2022.19061
DO - 10.1001/jama.2022.19061
M3 - Article
C2 - 36272098
AN - SCOPUS:85141888287
SN - 0002-9955
VL - 328
SP - 1730
EP - 1739
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 17
ER -